Investment
Features
FeesSafety
Academy
More
Pluang+

Bitcoin's Puell Multiple shows mining revenue above average but doesn't confirm market recovery.

Protocol Fundamentals
05 Oct 2026
Tokenpost
View Source
Neutral
Bitcoin's Puell Multiple shows mining revenue above average but doesn't confirm market recovery.

The Puell Multiple, an indicator for Bitcoin mining revenue, compares daily revenue to its 365-day average. A value above 1 means current daily revenue exceeds the yearly average, signaling potentially higher miner income. However, a single reading above 1 does not guarantee a sustained market recovery or reflect miners' financial pressures or behaviors. This metric provides context but should not be used alone to assess market health.

The Bitcoin Puell Multiple measures mining revenue relative to its yearly average, providing a context for market health. For readers following cryptocurrency markets, here is Pluang's market snapshot as of Oct 06, 2026 00:32 WIB: Among 50 major cryptocurrencies, 22 rose and 27 fell. Kusama (KSM) fell 2.75% to Rp90.852 with 89% of orders selling, contrasting with Aave (AAVE), which rose 2.63% to Rp3.298.886 and had a majority buy order activity at 54%. Harmony (ONE) dropped 2.31% to Rp41, with 66% of orders buying despite the price decline.

More News

Applied Digital eyes $1B net income by 2027 amid AI data center expansion, Q1 loss expected.

Applied Digital eyes $1B net income by 2027 amid AI data center expansion, Q1 loss expected.

Applied Digital is set to report a fiscal Q1 loss of $0.30 per share on $116.3 million revenue, reflecting ongoing investments in AI and high-performance data centers. The company has expanded its Polaris Forge 1 campus to 250 MW operational capacity...

Company Fundamentals
Bullish
52 minutes ago
Needham raises Vaxcyte price target after strong Phase 3 trial of VAX-31 vaccine

Needham raises Vaxcyte price target after strong Phase 3 trial of VAX-31 vaccine

Investment firm Needham increased its price target for Vaxcyte to $122 from $110 following positive Phase 3 trial results for Vaxcyte's VAX-31 pneumococcal vaccine. The vaccine met all primary endpoints in the OPUS-1 trial, showing noninferiority to ...

Analyst Insights
Bullish
1 hour ago
GMAB's Rina-S shows 45.9% response in ovarian cancer trial, advancing to Phase 3 studies.

GMAB's Rina-S shows 45.9% response in ovarian cancer trial, advancing to Phase 3 studies.

GMAB's investigational drug Rina-S demonstrated a 45.9% confirmed response rate in a Phase 1/2 trial for platinum-resistant ovarian cancer, with a median response duration of 12.1 months and median progression-free survival of 9.5 months. Despite ser...

Market News
Bullish
2 hours ago
NVIDIA price target raised to $345 on strong AI chip demand and earnings growth.

NVIDIA price target raised to $345 on strong AI chip demand and earnings growth.

BNP Paribas Exane raised NVIDIA's price target from $285 to $345 due to strong demand for its AI chips, signaling potential upside of about 45.6% from the current price. NVIDIA shares have gained about 25% in 2026, driven by growth in AI infrastructu...

Analyst Insights
Bullish
3 hours ago
Solana's Stocklana hackathon ends with 604 projects competing for $126K in tokenized stock trading prizes.

Solana's Stocklana hackathon ends with 604 projects competing for $126K in tokenized stock trading prizes.

The Solana Foundation concluded its Stocklana hackathon with 604 project submissions competing for a $126,000 prize pool focused on tokenized stocks that trade 24/7 on blockchain. The event tested demand for around-the-clock trading tools and debuted...

Protocol Fundamentals
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App